Leveraging the immense potential of Cell Penetrating Alphabodies

Partnering objectives

Complix is engaging in partnerships with other biotech and pharma companies to leverage the significant potential of its Cell Penetrating Alphabody (CPAB) platform and to develop novel therapeutics for treatment of important diseases.

Complix is currently engaged in active collaborations and in partnering discussions relating to CPAB platform applications in oncology, immuno-oncology, autoimmunity and CNS diseases.